Trial · NCT02096354
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | RRx-001 Followed by Irinotecan | 8.6 | 95% Confidence Interval 4.8 to NA | months | |
| Overall Survival | Regorafenib Followed by Irinotecan | 4.7 | 95% Confidence Interval 2.2 to NA | months | |
| Progression Free Survival | RRx-001 Followed by Irinotecan | 6.1 | 95% Confidence Interval 3.7 to NA | months | |
| Progression Free Survival | Regorafenib Followed by Irinotecan | 1.7 | 95% Confidence Interval 0.7 to NA | months | |
| Number of Adverse Events | RRx-001 Followed by Irinotecan | CTCAE Grade 1 | 184 | Number of total adverse events | |
| Number of Adverse Events | Regorafenib Followed by Irinotecan | CTCAE Grade 1 | 87 | Number of total adverse events | |
| Number of Adverse Events | RRx-001 Followed by Irinotecan | CTCAE Grade 2 | 76 | Number of total adverse events | |
| Number of Adverse Events | Regorafenib Followed by Irinotecan | CTCAE Grade 2 | 48 | Number of total adverse events | |
| Number of Adverse Events | RRx-001 Followed by Irinotecan | CTCAE Grade 3 | 15 | Number of total adverse events | |
| Number of Adverse Events | Regorafenib Followed by Irinotecan | CTCAE Grade 3 | 15 | Number of total adverse events | |
| Number of Adverse Events | RRx-001 Followed by Irinotecan | CTCAE Grade 4 | 0 | Number of total adverse events | |
| Number of Adverse Events | Regorafenib Followed by Irinotecan | CTCAE Grade 4 | 0 | Number of total adverse events | |
| Number of Adverse Events | RRx-001 Followed by Irinotecan | CTCAE Grade 5 | 0 | Number of total adverse events | |
| Number of Adverse Events | Regorafenib Followed by Irinotecan | CTCAE Grade 5 | 0 | Number of total adverse events | |
| Objective Response Rate | RRx-001 Followed by Irinotecan | Partial Response | 5 | Participants | |
| Objective Response Rate | Regorafenib Followed by Irinotecan | Partial Response | 0 | Participants | |
| Objective Response Rate | RRx-001 Followed by Irinotecan | Stable Disease | 12 | Participants | |
| Objective Response Rate | Regorafenib Followed by Irinotecan | Stable Disease | 4 | Participants | |
| Objective Response Rate | RRx-001 Followed by Irinotecan | Progressive Disease | 6 | Participants | |
| Objective Response Rate | Regorafenib Followed by Irinotecan | Progressive Disease | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02096354/results